MISCAN: estimating lead‐time and over‐detection by simulation

To estimate the mean lead‐time and rate of over‐detection associated with screening for prostate cancer with prostate‐specific antigen.

[1]  L. M. Franks.  Latent carcinoma of the prostate. , 1954, The Journal of pathology and bacteriology.

[2]  J D Habbema,et al.  The MISCAN simulation program for the evaluation of screening for disease. , 1985, Computer methods and programs in biomedicine.

[3]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[4]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[5]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[6]  H. Carter,et al.  Natural history of changes in prostate specific antigen in early stage prostate cancer. , 1994, The Journal of urology.

[7]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[8]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[9]  László Tabár,et al.  Quantitative Interpretation of Age-Specific Mortality Reductions From the Swedish Breast Cancer-Screening Trials , 1995 .

[10]  H. D. de Koning,et al.  Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. , 1995, Journal of the National Cancer Institute.

[11]  E. Feuer,et al.  Asymptomatic incidence and duration of prostate cancer. , 1998, American journal of epidemiology.

[12]  J A Hanley,et al.  Screening for prostate cancer: estimating the magnitude of overdetection. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[13]  S. Ciatto,et al.  Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.

[15]  Rob Boer,et al.  The MISCAN-COLON Simulation Model for the Evaluation of Colorectal Cancer Screening , 1999, Comput. Biomed. Res..

[16]  F. Labrie,et al.  Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial , 1999, The Prostate.

[17]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. , 1999, Journal of the National Cancer Institute.

[18]  J. Habbema,et al.  Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam) , 1999, International journal of cancer.

[19]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[20]  G. Stemmermann,et al.  Comparative studies of prostate cancer in Japan versus the United States. A review. , 2000, Urologic oncology.

[21]  J. Hugosson,et al.  Would prostate cancer detected by screening withprostate‐specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population‐based studies in Sweden , 2000, BJU international.

[22]  F. Labrie,et al.  Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer , 2000, The Prostate.

[23]  D. Gunnell,et al.  International trends in prostate‐cancer mortality in the “PSA era” , 2001, International journal of cancer.

[24]  A. Aromaa,et al.  Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. , 2001, The Journal of urology.

[25]  G Bartsch,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001, Urology.

[26]  Harry J de Koning,et al.  Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial , 2002, International journal of cancer.

[27]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[28]  I. Bairati,et al.  PSA screening and prostate cancer mortality. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[29]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[30]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[31]  T. Tammela,et al.  Lead-time in prostate cancer screening (Finland) , 2002, Cancer Causes & Control.